Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 PB Ratio is 12.98 as of Aug. 12, 2026, which is 9% above its 10-year median of 11.89. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks worse than 89.69% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Dr. Lal PathLabs's share price is ₹1949.90. Dr. Lal PathLabs's Book Value per Share for the quarter that ended in Jun. 2026 was ₹150.21. Hence, Dr. Lal PathLabs's PB Ratio of today is 12.98.
Warning Sign:
Dr. Lal PathLabs Ltd stock PB Ratio (=12.98) is close to 1-year high of 12.98.
The historical rank and industry rank for Dr. Lal PathLabs's PB Ratio or its related term are showing as below:
NSE:LALPATHLAB'
s PB Ratio Range Over the Past 10 Years
Min: 7.94 Med: 11.89 Max: 22.55
Current: 12.98
During the past 13 years, Dr. Lal PathLabs's highest PB Ratio was 22.55. The lowest was 7.94. And the median was 11.89.
NSE:LALPATHLAB's PB Ratio is ranked worse than 89.69% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21
vs NSE:LALPATHLAB: 12.98
During the past 12 months, Dr. Lal PathLabs's average Book Value Per Share Growth Rate was 15.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Dr. Lal PathLabs was 43.30% per year. The lowest was 12.70% per year. And the median was 20.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Dr. Lal PathLabs PB Ratio Related Terms
Dr. Lal PathLabs PB Ratio Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: PB Ratio Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a PB Ratio of 12.98 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dr. Lal PathLabs and its competitors. This is near median its historical median of 11.89. Over the past decade, Dr. Lal PathLabs' PB Ratio has ranged from 7.94 to 22.55. According to the industry distribution chart, Dr. Lal PathLabs ranks #174 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 89.7%.
Is Dr. Lal PathLabs' PB Ratio too high?
Dr. Lal PathLabs' current PB Ratio of 12.98 is near median its 10-year median of 11.89. Over the past 10 years, this metric has ranged from a low of 7.94 to a high of 22.55. The Medical Diagnostics & Research industry median PB Ratio is 2.21. Dr. Lal PathLabs' value of 12.98 is 487.3% above this industry median. Based on the distribution chart, Dr. Lal PathLabs ranks #174 out of 194 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #174 out of 194 companies for PB Ratio. This places Dr. Lal PathLabs in the lower half of its industry. The industry median PB Ratio is 2.21. Dr. Lal PathLabs' value of 12.98 is 487.3% above this benchmark. Historically, Dr. Lal PathLabs' own PB Ratio has ranged from 7.94 to 22.55 over the past decade. While the company's 10-year median is 11.89 vs. the industry median of 2.21, Dr. Lal PathLabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.21, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Lal PathLabs's current PB Ratio of 12.98 is 487.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current PB Ratio is 12.98, which is near median its own 10-year median of 11.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current PB Ratio is 12.98, which is near median its 10-year median of 11.89 and 487.3% above the Medical Diagnostics & Research industry median of 2.21. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current PB Ratio is 12.98 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
PB Ratio: 12.98 (near median its 10-year median of 11.89)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
Industry Position: 487.3% above the Medical Diagnostics & Research median (#174 of 194)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
